PTC Therapeutics, Inc. (PTCT) Total liabilities 2016–2025
PTC Therapeutics, Inc. (PTCT) total liabilities at each fiscal year-end, per SEC filings.
$3.1BFY2025 · since FY2016: $149.8M → $3.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.1B | +10.7% |
| FY2024 | $2.8B | +3.3% |
| FY2023 | $2.7B | +32.2% |
| FY2022 | $2.1B | +6.0% |
| FY2021 | $1.9B | +12.2% |
| FY2020 | $1.7B | +67.7% |
| FY2019 | $1.0B | +34.0% |
| FY2018 | $768.5M | +226.7% |
| FY2017 | $235.2M | +57.1% |
| FY2016 | $149.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTCT financial trends
PTCT RevenuePTCT Net incomePTCT Net marginPTCT Gross profitPTCT Gross marginPTCT Operating incomePTCT Operating marginPTCT Operating cash flowPTCT Free cash flowPTCT Capital expendituresPTCT Return on equityPTCT Stock buybacksPTCT Dividends paidPTCT Total assetsPTCT Shareholders’ equityPTCT overview →